CDNA logo

CAREDX INC

CDNANASDAQ
๐Ÿ† #1805 by market capEarnings Nov 2 ยท PostUS Equity
$47.23โ–ผ $0.03 (โˆ’0.07%)
Live
1hโ–ฒ 0.3%
24hโ–ผ 0.1%
7dโ–ฒ 3.9%
14dโ–ฒ 33.4%
30dโ–ฒ 64.0%
1yโ–ฒ 278.7%
๐ŸฆMarket Cap
$2.44B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+13.8%
Healthy
๐Ÿ“ŠGross Margin
70.6%
High
๐Ÿ’ตFCF Margin
18.6%
Healthy
โš–๏ธP/S Ratio
5.3x
Fair
Otter Score
46
Weak

Trading Snapshot

Day Range
$46.86 โ€“ $47.86
52-Week Range
$11.27 โ€“ $49.76
Volume
$2.86B
Avg Volume
$2.16B
Shares Outstanding
51.7M
Next Earnings
Oct 16, 2026

Fundamentals Snapshot

Annual Revenue
$380M
Last Q Revenue
$132M
P/E Ratio
21.9
P/S Ratio
5.3x
EPS (TTM)
$2.16
Dividend Yield
0.00%

Why Investors Own CDNA

  • โœ“High-growth profile โ€” revenue up +16.5% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 37% gross margin and 9% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$380Mโ–ฒ +13.2% YoY
Gross Margin (TTM)
37.0%โ–ผ โˆ’0.2% YoY
Operating Income (TTM)
$125Mโ–ฒ +13.2% YoY
Free Cash Flow (TTM)
$34Mโ–ฒ +13.2% YoY

About CAREDX INC

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
46/100

Analyst Ratings

โ“˜
Consensus
Buy
13 analysts
Strong Buy5
Buy3
Hold5
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

ChartMillยท6d ago

CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentals

CareDx stock aligns with Navellier's growth rules: accelerating earnings, rising estimates, margin expansion, high ROE. A momentum-oriented pick worth review.

๐Ÿ›ฐ๏ธ
Benzingaยท6d ago

BTIG Maintains Buy on CareDx, Raises Price Target to $60

BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $45 to $60.

Benzingaยท9d ago

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday

Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.

Benzingaยท12d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at

๐Ÿ›ฐ๏ธ
Benzingaยท12d ago

HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral and maintains $46 price target.

SeekingAlphaยท12d ago

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

CareDx, Inc. (CDNA) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsNina DekaJohn Hanna - President, CEO & DirectorKeith Kennedy -...